NCT06169540 (SEAL-HF) is a clinical trial in CHF, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT06169540?

NCT06169540 is sponsored by Massachusetts General Hospital.

What condition does NCT06169540 study?

NCT06169540 studies CHF, ADHF, Control.

Is NCT06169540 still recruiting?

NCT06169540 is currently recruiting now. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT06169540: SEAL-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)

Recruiting now Last updated 13 November 2025

What this trial tests

trial in CHF in 90 participants. Currently enrolling.

Timeline

19 April 2023

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	90
Start date	19 April 2023
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across United States

Conditions studied

CHF — all drugs for CHF →
ADHF — all drugs for ADHF →
Control — all drugs for Control →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with CHF or ADHF. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.
Tran HL, Zheng W, Issadore DA, Im H, et al · · 2025 · cited 25× · PMID 40720603 · DOI 10.1021/acsnano.5c00706
Extracellular Vesicles in Diabetic Cardiomyopathy-State of the Art and Future Perspectives.
Zygmunciak P, Stróżna K, Błażowska O, Mrozikiewicz-Rakowska B. · · 2024 · cited 5× · PMID 38892303 · DOI 10.3390/ijms25116117
Extracellular Vesicles in Calcific Aortic Valve Disease: From Biomarkers to Drug Delivery Applications.
Cook-Calvete A, Delgado-Marin M, Fernandez-Rodriguez B, Zaragoza C, et al · · 2025 · PMID 41301466 · DOI 10.3390/biom15111548
Extracellular vesicles in cardiovascular diseases: pathogenic mediators, diagnostic tools, and therapeutic vectors.
Li T, Wang W, Qin Z, Chen Y, et al · · 2025 · PMID 41132253 · DOI 10.3389/fcvm.2025.1666589

Verify or expand the search:

Other recruiting trials for CHF

Currently open trials in the same condition.

NCT05423652 — Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound · NA · active not recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06169540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06169540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing